State of Israel
|
Not Applicable
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Title of each class of securities to be registered (1)
|
Amount to be registered (1)
|
Proposed maximum aggregate price per unit (2)
|
Proposed maximum aggregate offering price (1)
|
Amount of registration fee (3)(4)
|
Ordinary Shares, par value NIS 0.01 per share (5)
|
||||
Debt Securities
|
||||
Warrants to purchase American Depositary Shares
|
||||
Units (6)
|
||||
Total
|
$150,000,000
|
$14,647.04
|
(1) |
These offered securities may be sold separately, together or as units with other offered securities. An indeterminate aggregate initial offering price or number of securities of each identified class is being registered as may from time to time be issued at indeterminate prices, with an aggregate public offering price not to exceed $150,000,000. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities or that are issued in units or represented by depositary shares. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this registration statement shall be deemed to cover any additional number of securities as may be offered or issued from time to time upon stock splits, stock dividends, recapitalizations or similar transactions. Pursuant to Rule 457(j) of the Securities Act, this includes such indeterminate number of shares of common stock as are issuable upon conversion of debt securities and warrants, indeterminate number of shares of common stock, debt securities or warrants issuable upon separation of units or indeterminate number of such securities pursuant to the anti-dilution provisions of such securities. No additional consideration will be received for such securities and, therefore, no registration fee is required pursuant to Rule 457(i) under the Securities Act. For debt securities issued with an original issue discount, the amount to be registered is calculated as the initial accreted value of such debt securities.
|
(2) |
Not required to be included in accordance with General Instruction II.C of Form F-3 under the Securities Act.
|
(3) |
Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include unsold securities previously registered by the Registrant on the Registrant’s registration statement (File No. 333-205700) filed on July 16, 2015, and declared effective on October 16, 2015, or the 2015 Registration Statement. The 2015 Registration Statement registered the offer and sale of an indeterminate number of ordinary shares, an indeterminate number of debt securities, an indeterminate number of warrants to purchase American Depositary Shares, and an indeterminate number of units, having an aggregate initial offering price of $75,000,000, a portion which remains unsold as of the date of filing this registration statement. The Registrant has determined to include in this registration statement certain unsold securities under the 2015 Registration Statement with an aggregate offering price of $34,664,054, or the Unsold Securities. Pursuant to Rule 415(a)(6) under the Securities Act, the filing fee of $4,027.96 relating to the Unsold Securities under the 2015 Registration Statement will continue to be applied to the Unsold Securities registered pursuant to this registration statement. The Registrant is also registering new securities on this registration statement with an aggregate initial offering price of $115,335,946, or the New Securities, which aggregate offering price is not specified as to each class of security (see footnote (2)). The proposed maximum aggregate offering price has been estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act and corresponds to the New Securities being registered hereby and not to the Unsold Securities carried over from the 2015 Registration Statement. To the extent that, after the filing date hereof and prior to the effectiveness of this registration statement, the Registrant sells any Unsold Securities pursuant to the 2015 Registration Statement, the Registrant will identify in a pre-effective amendment to this registration statement the updated amount of Unsold Securities from the 2015 Registration Statement to be included in this registration statement pursuant to Rule 415(a)(6) and the updated amount of New Securities to be registered on this registration statement. Pursuant to Rule 415(a)(6) under the Securities Act, the offering of the Unsold Securities under the 2015 Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement.
|
(4) |
The total filing fee of $14,647.04 paid by the Registrant in connection with this registration statement corresponds to the registration of the New Securities and not the Unsold Securities in accordance with Rule 415(a)(6). See also footnote (3) above.
|
(5) |
American Depositary Shares issuable upon deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6EF (File No. 333-218969). Each American Depositary Share represents one (1) ordinary share.
|
(6) |
Units will be issued under a unit agreement or indenture and will represent an interest of one or more ordinary shares, warrants, debt securities, or any combination of such securities.
|
· |
American Depositary Shares, or ADSs;
|
· |
ordinary shares;
|
· |
debt securities;
|
· |
warrants to purchase ADSs; and
|
· |
units consisting of two or more of the foregoing.
|
Page | |
1
|
|
2
|
|
3
|
|
4
|
|
5
|
|
6
|
|
7
|
|
8
|
|
14
|
|
20
|
|
33
|
|
35
|
|
36
|
|
37
|
|
40
|
|
41
|
|
42
|
|
43
|
|
44
|
|
II - 1
|
|
II - 5
|
|
II - 6
|
|
II - 7
|
· |
the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts;
|
· |
our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;
|
· |
our receipt of regulatory approvals for our therapeutic candidates and the timing of other regulatory filings and approvals;
|
· |
the clinical development, commercialization and market acceptance of our therapeutic candidates;
|
· |
our ability to establish and maintain corporate collaborations;
|
· |
our ability to integrate new therapeutic candidates and new personnel;
|
· |
the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials;
|
· |
the implementation of our business model and strategic plans for our business and therapeutic candidates;
|
· |
the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;
|
· |
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
|
· |
competitive companies, technologies and our industry; and
|
· |
statements as to the impact of the political and security situation in Israel on our business.
|
Year Ended December 31,*
|
Nine Months Ended September 30,
|
|||||||||||||||
2012
|
2013
|
2014
|
2015
|
2016
|
2017
|
|||||||||||
(20,236) |
|
(16,301) |
|
(10,512) |
|
(14,401) |
|
(15,841) |
|
(16,995) |
|
U.S. $
|
||||||||
Price Per ADS
|
||||||||
High
|
Low
|
|||||||
Annual:
|
||||||||
2016
|
1.30
|
0.75
|
||||||
2015
|
2.84
|
1.23
|
||||||
2014
|
3.07
|
1.23
|
||||||
2013
|
4.75
|
1.58
|
||||||
2012
|
5.55
|
2.23
|
||||||
Quarterly:
|
||||||||
Fourth Quarter 2017 (through December 26, 2017)
|
1.31
|
|
0.94
|
|
||||
Third Quarter 2017
|
1.18
|
0.81
|
||||||
Second Quarter 2017
|
0.92
|
0.82
|
||||||
First Quarter 2017
|
1.30
|
0.88
|
||||||
Fourth Quarter 2016
|
1.16
|
0.92
|
||||||
Third Quarter 2016
|
1.28
|
0.75
|
||||||
Second Quarter 2016
|
1.02
|
0.79
|
||||||
First Quarter 2016
|
1.30
|
0.90
|
||||||
Fourth Quarter 2015
|
1.62
|
1.24
|
||||||
Third Quarter 2015
|
2.65
|
1.23
|
||||||
Second Quarter 2015
|
2.66
|
1.85
|
||||||
First Quarter 2015
|
2.84
|
1.71
|
||||||
Most Recent Six Months:
|
||||||||
December 2017 (through December 26, 2017)
|
1.14
|
|
1.05
|
|
||||
November 2017
|
1.14
|
0.94
|
||||||
October 2017
|
1.31
|
1.03
|
||||||
September 2017
|
1.16
|
1.03
|
||||||
August 2017
|
1.18
|
1.02
|
||||||
July 2017
|
1.07
|
0.81
|
||||||
June 2017
|
0.87
|
0.82
|
NIS
|
U.S. $
|
|||||||||||||||
Price Per
Ordinary Share |
Price Per
Ordinary Share |
|||||||||||||||
High
|
Low
|
High
|
Low
|
|||||||||||||
Annual:
|
||||||||||||||||
2016
|
5.21
|
3.07
|
1.34
|
0.79
|
||||||||||||
2015
|
10.23
|
4.94
|
2.57
|
1.27
|
||||||||||||
2014
|
10.49
|
4.76
|
3.01
|
1.24
|
||||||||||||
2013
|
17.99
|
5.90
|
4.89
|
1.62
|
||||||||||||
2012
|
21.15
|
8.92
|
5.58
|
2.32
|
||||||||||||
Quarterly:
|
||||||||||||||||
Fourth Quarter 2017 (through December 26, 2017)
|
4.36
|
|
3.35
|
|
1.30
|
|
0.94
|
|
||||||||
Third Quarter 2017
|
4.19
|
2.90
|
1.16
|
0.82
|
||||||||||||
Second Quarter 2017
|
3.65
|
2.92
|
1.01
|
0.82
|
||||||||||||
First Quarter 2017
|
4.67
|
3.52
|
1.26
|
0.92
|
||||||||||||
Fourth Quarter 2016
|
4.31
|
3.48
|
1.12
|
0.90
|
||||||||||||
Third Quarter 2016
|
4.60
|
3.07
|
1.22
|
0.80
|
||||||||||||
Second Quarter 2016
|
3.92
|
3.07
|
1.04
|
0.79
|
||||||||||||
First Quarter 2016
|
5.21
|
3.67
|
1.34
|
0.94
|
||||||||||||
Fourth Quarter 2015
|
6.16
|
5.05
|
1.58
|
1.30
|
||||||||||||
Third Quarter 2015
|
10.21
|
4.94
|
2.70
|
1.27
|
||||||||||||
Second Quarter 2015
|
9.83
|
7.36
|
2.61
|
1.92
|
||||||||||||
First Quarter 2015
|
10.23
|
6.70
|
2.57
|
1.72
|
||||||||||||
Most Recent Six Months:
|
||||||||||||||||
December 2017 (through December 26, 2017)
|
4.05
|
|
3.73
|
|
1.14
|
|
1.06
|
|
||||||||
November 2017
|
3.93
|
3.35
|
1.12
|
0.95
|
||||||||||||
October 2017
|
4.36
|
3.64
|
1.24
|
1.03
|
||||||||||||
September 2017
|
4.02
|
3.45
|
1.14
|
0.98
|
||||||||||||
August 2017
|
4.19
|
3.64
|
1.16
|
1.02
|
||||||||||||
July 2017
|
3.70
|
2.90
|
1.04
|
0.82
|
||||||||||||
June 2017
|
3.12
|
2.92
|
0.88
|
0.82
|
· |
amendments to our Articles of Association;
|
· |
appointment or termination of our auditors;
|
· |
appointment of directors and appointment and dismissal of external directors;
|
· |
approval of acts and transactions requiring general meeting approval pursuant to the Companies Law;
|
· |
approval of our compensation policy for directors and office holders;
|
· |
compensation of directors and/or the principal executive officer, indemnification and change of the principal executive officer;
|
· |
increases or reductions of our authorized share capital;
|
· |
a merger; and
|
· |
the exercise of our Board of Director’s powers by a general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
|
· |
an appointment or removal of directors;
|
· |
an approval of transactions with office holders or interested or related parties;
|
· |
an approval of certain officer’s actions with regards to the officer’s fiduciary duties pursuant to section 254 to the Companies Law;
|
· |
an approval of a merger or any other matter in respect of which there is a provision in the articles of association providing that decisions of the general meeting may also be passed by written ballot;
|
· |
authorizing the chairman of the board of directors or his relative to act as the company’s chief executive officer or act with such authority; or authorize the company’s chief executive officer or his relative to act as the chairman of the board of directors or act with such authority; and
|
· |
other matters that may be prescribed by Israel’s Minister of Justice.
|
· |
make the rights available to all or certain holders of ADSs, by means of warrants or otherwise, if lawful and practically feasible; or
|
· |
attempt to sell those rights or warrants or other instruments.
|
· |
payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities; and
|
· |
satisfactory proof of the identity and genuineness of any signature or other information it deems necessary.
|
· |
we do not wish to receive a discretionary proxy;
|
· |
there is substantial shareholder opposition to the particular question; or
|
· |
the particular question would have an adverse impact on our shareholders.
|
· |
collect dividends and other distributions pertaining to deposited securities;
|
· |
sell rights as described under the heading “Dividends, other distributions and rights — Rights to subscribe for additional ordinary shares and other rights” above; and
|
· |
deliver deposited securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any rights or other property, in exchange for surrendered ADSs.
|
· |
taxes and other governmental charges;
|
· |
any applicable transfer or registration fees;
|
· |
certain cable and facsimile transmission charges as provided in the deposit agreement;
|
· |
any expenses incurred in the conversion of foreign currency;
|
· |
a fee of $5.00 or less per 100 ADSs (or a portion thereof) for the execution and delivery of ADSs and the surrender of ADSs, including if the deposit agreement terminates;
|
· |
a fee of $.05 or less per ADS (or portion thereof) for any cash distribution made pursuant to the deposit agreement;
|
· |
a fee for the distribution of securities pursuant to the deposit agreement;
|
· |
in addition to any fee charged under clause 6, a fee of $.05 or less per ADS (or portion thereof) per annum for Depositary services;
|
· |
a fee for the distribution of proceeds of rights that the Depositary sells pursuant to the deposit agreement; and
|
· |
any other charges payable by the Depositary, any of the Depositary’s agents, or the agents of the Depositary’s agents in connection with the servicing of shares or other deposited securities.
|
· |
are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;
|
· |
are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement;
|
· |
are not liable if we or it exercise discretion permitted under the deposit agreement;
|
· |
are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;
|
· |
have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;
|
· |
are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and
|
· |
may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.
|
· |
the designation or title of the series of debt securities;
|
· |
the total principal amount of the series of debt securities;
|
· |
the percentage of the principal amount at which the series of debt securities will be offered;
|
· |
the date or dates on which principal will be payable;
|
· |
the rate or rates (which may be either fixed or variable) and/or the method of determining such rate or rates of interest, if any;
|
· |
the date or dates from which any interest will accrue, or the method of determining such date or dates, and the date or dates on which any interest will be payable;
|
· |
whether any interest may be paid by issuing additional securities of the same series in lieu of cash (and the terms upon which any such interest may be paid by issuing additional securities);
|
· |
the terms for redemption, extension or early repayment, if any;
|
· |
the currencies in which the series of debt securities are issued and payable;
|
· |
whether the amount of payments of principal, premium or interest, if any, on a series of debt securities will be determined with reference to an index, formula or other method (which could be based on one or more currencies, commodities, equity indices or other indices) and how these amounts will be determined;
|
· |
the place or places, if any, other than or in addition to the Borough of Manhattan in the City of New York, of payment, transfer, conversion and/or exchange of the debt securities;
|
· |
the denominations in which the offered debt securities will be issued (if other than $1,000 and any integral multiple thereof for registered securities);
|
· |
the provision for any sinking fund;
|
· |
any restrictive covenants;
|
· |
any Events of Default (as defined below);
|
· |
whether the series of debt securities are issuable in certificated form;
|
· |
any provisions for defeasance or covenant defeasance;
|
· |
any provisions regarding any future changes or modifications of the terms of the series of debt securities in light of the requirements under applicable law for effecting such changes or modifications;
|
· |
any special Israeli and/or U.S. federal income tax implications, including, if applicable, Israeli and/or U.S. federal income tax considerations relating to original issue discount;
|
· |
whether and under what circumstances we will pay additional amounts in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities rather than pay the additional amounts (and the terms of this option);
|
· |
any provisions for convertibility or exchangeability of the debt securities into or for any other securities;
|
· |
whether the debt securities are subject to subordination and the terms of such subordination;
|
· |
whether the debt securities are secured or unsecured and the terms of any security interests;
|
· |
the listing, if any, on a securities exchange; and
|
· |
any other terms.
|
· |
how it handles securities payments and notices;
|
· |
whether it imposes fees or charges;
|
· |
how it would handle a request for the holders’ consent, if ever required;
|
· |
whether and how you can instruct it to send you debt securities registered in your own name so you can be a holder, if that is permitted in the future for a particular series of debt securities;
|
· |
how it would exercise rights under the debt securities if there were a default or other event triggering the need for holders to act to protect their interests; and
|
· |
if the debt securities are in book-entry form, how the depositary’s rules and procedures will affect these matters.
|
· |
An investor cannot cause the debt securities to be registered in his or her name and cannot obtain certificates for his or her interest in the debt securities, except in the special situations we describe below.
|
· |
An investor will be an indirect holder and must look to his or her own bank or broker for payments on the debt securities and protection of his or her legal rights relating to the debt securities, as we describe under “Issuance of Securities in Registered Form” above.
|
· |
An investor may not be able to sell interests in the debt securities to some insurance companies and other institutions that are required by law to own their securities in non-book-entry form.
|
· |
An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the debt securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective.
|
· |
The depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s interest in a global security. We and the trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way.
|
· |
If we redeem less than all the debt securities of a particular series being redeemed, DTC’s practice is to determine by lot the amount to be redeemed from each of its participants holding that series.
|
· |
An investor is required to give notice of the exercise of any option to elect repayment of its debt securities, through its participant, to the applicable trustee and to deliver the related debt securities by causing its participant to transfer its interest in those debt securities, on DTC’s records, to the applicable trustee.
|
· |
DTC requires that those who purchase and sell interests in a global security deposited in its book‑entry system use immediately available funds. Your broker or bank may also require you to use immediately available funds when purchasing or selling interests in a global security.
|
· |
Financial institutions that participate in the depositary’s book‑entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the debt securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.
|
· |
We do not pay interest on a debt security of the series within thirty (30) days of its due date.
|
· |
We do not pay the principal of, or any premium on, a debt security of the series on its due date.
|
· |
We do not deposit any sinking fund payment in respect of debt securities of the series within two (2) business days of its due date.
|
· |
We remain in breach of a covenant in respect of debt securities of the series for sixty (60) days after we receive a written notice of default stating we are in breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of debt securities of the series.
|
· |
We file for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur.
|
· |
Any other Event of Default in respect of debt securities of the series described in the applicable prospectus supplement occurs.
|
· |
You must give your trustee written notice that an Event of Default has occurred and remains uncured.
|
· |
The holders of at least 25% in principal amount of all outstanding debt securities of the relevant series must make a written request that the trustee take action because of the default and must offer reasonable indemnity to the trustee against the cost and other liabilities of taking that action.
|
· |
The trustee must not have taken action for sixty (60) days after receipt of the above notice and offer of indemnity.
|
· |
The holders of a majority in principal amount of the debt securities must not have given the trustee a direction inconsistent with the above notice during that sixty (60) day period.
|
· |
the payment of principal, any premium or interest; or
|
· |
in respect of a covenant that cannot be modified or amended without the consent of each holder.
|
· |
Where we merge out of existence or sell our assets, the resulting entity must agree to be legally responsible for our obligations under the debt securities.
|
· |
The merger or sale of assets must not cause a default on the debt securities and we must not already be in default (unless the merger or sale would cure the default). For purposes of this no‑default test, a default would include an Event of Default that has occurred and has not been cured, as described under “Events of Default” above. A default for this purpose would also include any event that would be an Event of Default if the requirements for giving us a notice of default or our default having to exist for a specific period of time were disregarded.
|
· |
We must deliver certain certificates and documents to the trustee.
|
· |
We must satisfy any other requirements specified in the prospectus supplement relating to a particular series of debt securities.
|
· |
change the stated maturity of the principal of, or interest on, a debt security;
|
· |
reduce any amounts due on a debt security;
|
· |
reduce the amount of principal payable upon acceleration of the maturity of a security following a default;
|
· |
adversely affect any right of repayment at the holder’s option;
|
· |
change the place (except as otherwise described in the prospectus or prospectus supplement) or currency of payment on a debt security;
|
· |
impair your right to sue for payment;
|
· |
adversely affect any right to convert or exchange a debt security in accordance with its terms;
|
· |
modify the subordination provisions in the indenture in a manner that is adverse to holders of the debt securities;
|
· |
reduce the percentage of holders of debt securities whose consent is needed to modify or amend the indenture;
|
· |
reduce the percentage of holders of debt securities whose consent is needed to waive compliance with certain provisions of the indenture or to waive certain defaults;
|
· |
modify any other aspect of the provisions of the indenture dealing with supplemental indentures, modification and waiver of past defaults, changes to the quorum or voting requirements or the waiver of certain covenants; and
|
· |
change any obligation we have to pay additional amounts.
|
· |
If the change affects only one series of debt securities, it must be approved by the holders of a majority in principal amount of that series.
|
· |
If the change affects more than one series of debt securities issued under the same indenture, it must be approved by the holders of a majority in principal amount of all of the series affected by the change, with all affected series voting together as one class for this purpose.
|
· |
For original issue discount securities, we will use the principal amount that would be due and payable on the voting date if the maturity of these debt securities were accelerated to that date because of a default.
|
· |
For debt securities whose principal amount is not known (for example, because it is based on an index), we will use the principal face amount at original issuance or a special rule for that debt security described in the prospectus supplement.
|
· |
For debt securities denominated in one (1) or more foreign currencies, we will use the dollar equivalent.
|
· |
If the debt securities of the particular series are denominated in dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates and any mandatory sinking fund payments or analogous payments.
|
· |
We must deliver to the trustee a legal opinion of our counsel confirming that, under current U.S. federal income tax law, we may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity.
|
· |
We must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the Investment Company Act of 1940, as amended, or the 1940 Act, and a legal opinion and officers’ certificate stating that all conditions precedent to covenant defeasance have been complied with.
|
· |
Defeasance must not result in a breach of the indenture or any of our other material agreements.
|
· |
Satisfy the conditions for covenant defeasance contained in any supplemental indentures.
|
· |
If the debt securities of the particular series are denominated in dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates and any mandatory sinking fund payments or analogous payments.
|
· |
We must deliver to the trustee a legal opinion confirming that there has been a change in current U.S. federal tax law or an IRS ruling that allows us to make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity. Under current U.S. federal tax law, the deposit and our legal release from the debt securities would be treated as though we paid you your share of the cash and notes or bonds at the time the cash and notes or bonds were deposited in trust in exchange for your debt securities and you would recognize gain or loss on the debt securities at the time of the deposit.
|
· |
We must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act and a legal opinion and officers’ certificate stating that all conditions precedent to defeasance have been complied with.
|
· |
Defeasance must not result in a breach of the indenture or any of our other material agreements.
|
· |
Satisfy the conditions for covenant defeasance contained in any supplemental indentures.
|
· |
only in fully registered certificated form;
|
· |
without interest coupons; and
|
· |
unless we indicate otherwise in the prospectus supplement, in denominations of $1,000 and amounts that are multiples of $1,000.
|
· |
our indebtedness (including indebtedness of others guaranteed by us), whenever created, incurred, assumed or guaranteed, for money borrowed, that we have designated as “Designated Senior Indebtedness” for purposes of the indenture and in accordance with the terms of the indenture (including any indenture securities designated as Designated Senior Indebtedness); and
|
· |
renewals, extensions, modifications and refinancings of any of this indebtedness.
|
· |
the offering price;
|
· |
the aggregate number or amount of underlying securities purchasable upon exercise of the warrants and the exercise price;
|
· |
the number of warrants being offered;
|
· |
the date, if any, after which the warrants and the underlying securities will be transferable separately;
|
· |
the date on which the right to exercise the warrants will commence, and the date on which the right will expire, or the Expiration Date;
|
· |
the number of warrants outstanding, if any;
|
· |
any material Israeli and/or U.S. federal income tax consequences;
|
· |
the terms, if any, on which we may accelerate the date by which the warrants must be exercised; and
|
· |
any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
|
· |
the trading price of the warrants;
|
· |
the price of the underlying securities at that time;
|
· |
the time remaining to expiration; and
|
· |
any related transaction costs.
|
· |
the date, if any, on and after which the units may be transferable separately;
|
· |
whether we will apply to have the units traded on a securities exchange or securities quotation system;
|
· |
any material Israeli and/or U.S. federal income tax consequences; and
|
· |
how, for Israeli and/or U.S. federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities.
|
· |
to or through one or more underwriters or dealers;
|
· |
in short or long transactions;
|
· |
directly to investors; or
|
· |
through agents.
|
· |
in privately negotiated transactions;
|
· |
in one or more transactions at a fixed price or prices, which may be changed from time to time;
|
· |
in “at-the-market offerings,” within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise;
|
· |
at prices related to those prevailing market prices; or
|
· |
at negotiated prices.
|
· |
the names of any underwriters, dealers or agents;
|
· |
any agency fees or underwriting discounts or commissions and other items constituting agents’ or underwriters’ compensation;
|
· |
any discounts or concessions allowed or reallowed or paid to dealers;
|
· |
details regarding over-allotment options under which underwriters may purchase additional securities from us, if any;
|
· |
the purchase price of the securities being offered and the proceeds we will receive from the sale;
|
· |
the public offering price; and
|
· |
the securities exchanges on which such securities may be listed, if any.
|
(1) |
Our Annual Report on Form 20-F for the year ended December 31, 2016 filed on March 23, 2017; and
|
(2) |
Our Current Reports on Form 6-K filed on January 9, 2017, January 23, 2017, January 26, 2017, February 13, 2017, March 23, 2017, March 30, 2017 (except with respect to item 7.01 therein), April 5, 2017, May 17, 2017, May 25, 2017, May 30, 2017, July 5, 2017, July 26, 2017, July 31, 2017, August 8, 2017, August 15, 2017, October 31, 2017, November 21, 2017, December 4, 2017 and December 5, 2017.
|
· |
the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;
|
· |
the prevailing law of the foreign state in which the judgments were rendered allows for the enforcement of judgments of Israeli courts;
|
· |
adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;
|
· |
the judgments are not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;
|
· |
the judgments were not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties;
|
· |
an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court;
|
· |
the judgment is not subject to any further appeal procedures; and
|
· |
the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.
|
· |
reasonable litigation expenses, including attorneys’ fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and
|
· |
reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a third party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for a crime that does not require proof of criminal intent.
|
· |
a breach of duty of care to the company or to a third party, including a breach arising out of the negligent conduct of an office holder;
|
· |
a breach of duty of loyalty to the company, provided the director or officer acted in good faith and had a reasonable basis to believe that the act would not prejudice the interests of the company; and
|
· |
financial liabilities imposed on the office holder for the benefit of a third party.
|
· |
a breach of duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;
|
· |
a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;
|
· |
an act or omission committed with intent to derive illegal personal benefit;
|
· |
a fine levied against the office holder; or
|
· |
against liabilities incurred by the office holder under an administrative proceeding initiated by the ISA under Chapters VIII-3, VIII-4 or IX-1 of the Israeli Securities Law (excluding indemnification or insurance for payment imposed on the office holder in favor of an injured party under such administrative procedure or expenses that the office holder incurred in connection with such administrative procedure).
|
(a) |
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 8 hereof, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
|
(b) |
The undersigned Registrant hereby undertakes:
|
(1) |
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
|
(i) |
To include any prospectus required by Section 10(a)(3) of the Securities Act;
|
(ii) |
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) that, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
|
(iii) |
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
|
(2) |
That for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
(3) |
To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering.
|
(4) |
To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished, provided that the Registrant includes in the prospectus, by means of a post‑effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act or Rule 3-19 of this chapter if such financial statements and information are contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Form F-3.
|
(5) |
That, for the purpose of determining liability under the Securities Act to any purchaser:
|
(i) |
If the Registrant is relying on Rule 430B:
|
(A) |
Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
|
(B) |
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Provided
,
however
, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or
|
(ii) |
If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.
Provided
,
however
, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
|
(6) |
That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:
|
(i) |
Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
|
(ii) |
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;
|
(iii) |
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and
|
(iv) |
Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
|
(c) |
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
(d) |
The undersigned Registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under Subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC under Section 305(b)(2) of the Trust Indenture Act.
|
BIOLINERX LTD. | |||
By:
|
/s/ Philip A. Serlin | ||
Philip A. Serlin | |||
Chief Executive Officer | |||
Name
|
Title
|
Date
|
||
/s/ Philip A. Serlin
|
Chief Executive Officer
(principal executive officer)
|
December 28, 2017
|
||
Philip A. Serlin
|
||||
/s/ Mali Zeevi
|
Chief Financial Officer
(principal financial officer and principal accounting officer)
|
December 28, 2017
|
||
Mali Zeevi
|
||||
/s/ Aharon Schwartz
|
Chairman of the Board
|
December 28, 2017
|
||
Aharon Schwartz, Ph.D
|
||||
/s/ Michael J. Anghel
|
Director
|
December 28, 2017
|
||
Michael J. Anghel, Ph.D.
|
||||
/s/ Nurit Benjamini
|
Director
|
December 28, 2017
|
||
Nurit Benjamini
|
||||
/s/ B.J. Bormann
|
Director
|
December 28, 2017
|
||
B.J. Bormann, Ph.D.
|
||||
/s/ Raphael Hofstein
|
Director
|
December 28, 2017
|
||
Raphael Hofstein, Ph.D.
|
||||
/s/ Avraham Molcho
|
Director
|
December 28, 2017
|
||
Avraham Molcho, M.D.
|
||||
/s/ Sandra Panem
|
Director
|
December 28, 2017
|
||
Sandra Panem, Ph.D.
|
||||
/s/ Miriam Katz
|
Authorized United States Representative
|
December 28, 2017
|
||
Vcorp Agent Services, Inc.
Miriam Katz, Assistant Secretary
|
BioLineRx Ltd.
Articles of Association of a Public Company
In accordance with
The Companies Law, 5759-1999
As of July 5, 2017
BioLineRx Ltd.
|
1. |
Name of Company
|
2. |
Goals of the Company
|
3. |
Interpretation
|
3.1 |
Any statement in the singular shall also include the plural and vice versa; any statement in the masculine shall also include the feminine and vice versa.
|
3.2 |
Except insofar as these Articles include special definitions of certain terms, any word and expression in these Articles shall have the meaning attributed thereto in the Companies Law, 5759-1999 (in these Articles – “
the Companies Law
,”) unless this contradicts the written matter or the content thereof.
|
3.3 |
To prevent doubt it is clarified that regarding matters regulated in the Companies Law in such manner that the arrangements in these matters may be conditioned in the Articles, and in cases in which these Articles do not include different provisions from those in the Companies Law, the provisions of the Companies Law shall apply.
|
3.4 |
It is hereby clarified that the provisions of the Articles of Association of the Company as detailed below are subject to the provisions of the Companies Law, the Securities Law, and any law.
|
4. |
The Share Capital of the Company and the Rights Attached to Shares
|
4.1 |
The registered capital of the Company is NIS 25,000,000, divided into 250,000,000 ordinary shares with a nominal value of NIS 0.10 each.
|
4.2 |
The ordinary shares shall entitle their owners to –
|
4.2.1 |
An equal right to participate in and vote at the general meetings of the Company, whether ordinary meetings or extraordinary meetings. Each of the shares in the Company shall entitle its owner present at the meeting and participating in the vote in person, by proxy, or by means of a letter of voting, to one vote;
|
4.2.2 |
An equal right to participate in the distribution of dividends, whether in cash or in benefit shares, in the distribution of assets, or in any other distribution, according to the proportionate nominal value of the shares held thereby;
|
4.2.3 |
An equal right to participate in the distribution of the surplus assets of the Company in the event of its liquidation in accordance with the proportionate nominal value of the shares held thereby.
|
4.3 |
The Board of Directors is entitled to issue shares and other convertible securities or securities that may be realized as shares up to the limit of the Company’s registered capital. For the purpose of calculating the limit of the registered capital, convertible securities or securities that may be realized as shares shall be considered to have been converted or realized as of their date of issue.
|
5. |
Limited Liability
|
6. |
Joint Shares and Share Certificates
|
6.1 |
The owner of a share registered in the registry of shareholders is entitled to receive from the Company, without payment and within a period of three months following the allocation or the registration of transfer, one share certificate stamped with the Company’s stamp regarding all the shares registered in his name, which certificate shall detail the number of shares. In the event of a jointly owned share, the Company shall issue one share certificate for all the joint owners of the share, and the delivery of such a certificate to one of the partners shall be considered delivery to them all.
|
6.2 |
A share certificate that has been defaced, destroyed, or lost may be renewed on the basis of such proof and guarantees as shall be required by the Company from time to time.
|
7. |
The Company’s Reliefs relating to Shares that Have Not Been Fully Paid
|
7.1 |
If any or all of the remuneration the shareholder undertook to pay the Company in return for his shares has not been paid by such date and on such conditions as established in the conditions for the allocation of his shares and/or in the payment request as stated in section 7.2 below, the Company is entitled, by way of a decision of the Board of Directors, to forfeit the shares whose remuneration has not been fully paid. The forfeiture of shares shall take place provided that the Company has sent the shareholder written warning of its intention to forfeit the shares after at least 7 days from the date of receipt of the warning, insofar as payment shall not be made during the period determined in the letter of warning.
|
7.2 |
If, in accordance with the conditions of allocation of the shares, there is no fixed date for the payment of any part of the price to be paid on account thereof, the Board of Directors is entitled, from time to time, to present payment requests to the shareholders on account of monies not yet removed for the shares they hold, and each shareholder shall be obliged to pay the Company the amount requested on the date determined as stated, provided that he shall receive prior notice of 14 days of the date and place of payment (hereinafter – “
the Payment Request
.”) The notification shall specify that non-payment by or before the determined date and in the specified place may lead to the forfeiture of the shares regarding which payment is requested. A Payment Request may be nullified or postponed to another date, all as shall be decided by the Board of Directors.
|
7.3 |
Unless otherwise determined in the conditions of allocations of the shares, a shareholder shall not be entitled to receive a dividend or to exercise any right as a shareholder on account of shares that have not yet been fully paid.
|
7.4 |
Persons who are the joint owners of a share shall be liable jointly and severally for payment of the amounts due to the Company on account of the share.
|
7.5 |
The content of this section shall not derogate from any other relief of the Company vis-à-vis a shareholder who fails to pay his debt to the Company on account of his shares.
|
8. |
Transfer of Shares
|
8.1 |
The Company’s shares are transferable.
|
8.2 |
The transfer of shares must be made in writing, and it shall be recorded only if –
|
8.2.1 |
A proper certificate for the transfer of shares, together with the certificates of the share intended for transfer, if such were issued, is delivered to the Company at its registered office. The certificate of transfer shall be signed by the transferor and by a witness confirming the signature of the transferor. In the event of the transfer of shares that are not fully paid as of the date of transfer, the certificate of transfer shall also be signed by the recipient of the share and by a witness testifying to the signature of the recipient; or
|
8.2.2 |
A court order for the amendment of the registration shall be delivered to the Company; or
|
8.2.3 |
It shall be proved to the Company that lawful conditions pertain for the transfer of the right to the share.
|
8.3 |
The transfer of shares that have not been fully paid requires the authorization of the Board of Directors, which is entitled to refuse to grant its authorization at its absolute discretion and without stating grounds therefore.
|
8.4 |
The recipient of the transfer shall be considered the shareholder regarding the transferred shares from the moment of the registration of his name in the registry of shareholders.
|
9. |
Changes in Capital
|
9.1 |
The general meeting is entitled to increase the Company’s registered share capital by creating new shares of an existing type or a new type, all as shall be determined in the decision of the general meeting.
|
9.2 |
The general meeting is entitled to nullify registered share capital that has not yet been allocated, provided that there is no commitment, including a conditioned commitment, by the Company to allocate the shares.
|
9.3 |
The general meeting shall be entitled, subject to the provisions of any law:
|
9.3.1 |
To unify and redivide its share capital, or any part thereof, into shares of a nominal value greater than the nominal value of the existing shares.
|
9.3.2 |
To divide, by way of the redivision of any or all of the existing shares, its share capital into shares of a nominal value smaller than the nominal value of the existing shares.
|
9.3.3 |
To reduce its share capital and any reserved fund for the repayment of capital in such manner and on such conditions and with the receipt of such authorization as shall be required by the Companies Law.
|
10. |
Changes in the Rights of Share Types
|
10.1 |
Unless otherwise stated in the conditions of issue of the shares, and subject to the provisions of any law, the rights of any share type may be changed following a decision of the Company’s Board of Directors, and with the authorization of the general meeting of shareholders of that type, or with the written consent of all the shareholders of that type. The provisions of the Company’s Articles of Association regarding general meetings shall apply,
mutatis mutandis
, to a general meeting of type shareholders.
|
10.2 |
The rights granted to the holders of shares of a specific type issued with special rights shall not be considered to have been changed by virtue of the creation or issue of additional shares of equal grade, unless otherwise conditioned in the conditions of issue of the said shares.
|
11. |
General Meetings
|
11.1 |
Company decisions on the following matters shall be taken at the general meeting –
|
11.1.1 |
Changes to the Articles;
|
11.1.2 |
Exercising the authorities of the Board of Directors in the event that the Board of Directors is unable to perform its function;
|
11.1.3 |
Appointment of the auditing accountant of the Company and the cessation of employment thereof;
|
11.1.4 |
Appointment of directors, including external directors;
|
11.1.5 |
Authorization of actions and transactions requiring the authorization of the general meeting in accordance with the provisions of the Companies Law and any other law;
|
11.1.6 |
Increasing and decreasing the registered share capital;
|
11.1.7 |
Merger as defined in the Companies Law.
|
11.2 |
Subject to the provisions of the law, the general meeting is entitled to assume authorities granted to another organ in the Company, including the Board of Directors, for a particular matter or for a given period of time.
|
12. |
Convening of General Meetings
|
12.1 |
General meetings shall be convened at least once a year at such a venue and on such a date as shall be determined by the Board of Directors, and subject to the provisions of the law, but not later than 15 months after the previous general meeting. These general meetings shall be called “annual meetings.” The remaining meetings of the Company shall be called “extraordinary meetings.”
|
12.2 |
The agenda at the annual meeting shall include discussion of the report of the Board of Directors and financial statements as required by law. The annual meeting shall appoint an auditing accountant; shall appoint the directors in accordance with these Articles; and shall discuss all other matters to be discussed at the annual meeting of the Company in accordance with these Articles or in accordance with the Companies Law, as well as any other matter as shall be determined by the Board of Directors.
|
12.3 |
The Board of Directors is entitled to convene an extraordinary meeting in accordance with its decision, and must convene a general meeting if a written request is received from any of the following (hereinafter – “
Request to Convene
:”)
|
12.3.1 |
Two directors or one-fourth of the incumbent directors; and/or
|
12.3.2 |
One or more shareholders holding at least five percent of the issued capital and at least one percent of the voting rights in the Company; and/or
|
12.3.3 |
One or more shareholders holding at least five percent of the voting rights in the Company.
|
12.4 |
Any Request to Convene must specify the goals for whose purpose the meeting is to be convened, and shall be signed by those requesting the convening and delivered at the Company’s registered office. The request may consist of a number of documents of identical format, each signed by one or more individuals making the request.
|
12.5 |
A Board of Directors required to convene an extraordinary meeting shall convene such meeting within twenty-one days from the date on which the Request to Convene was submitted thereto, for a date determined in an invitation in accordance with section 12.6 below and subject to any law.
|
12.6 |
Notification of the members of the Company regarding the convening of a general meeting shall be published or delivered to all the shareholders registered in the registry of shareholders in the Company in accordance with the requirements of the law. The notification shall include the agenda, the proposed decisions, and arrangements regarding voting in writing.
|
13. |
Discussion at General Meetings
|
13.1 |
The discussion at the general meeting shall be opened only if a legal quorum is present at the time the discussion begins. A legal quorum is the presence of at least two shareholders holding at least 25 percent of the voting rights (including presence by means of proxy or through a letter of voting) within one half-hour from the time specified for the opening of the meeting.
|
13.2 |
If, at the end of one half-hour from the time specified for the opening of the meeting, no legal quorum is present, the meeting shall be postponed by one week, to the same day, the same hour, and the same venue, or to a later date, if specified on the invitation to the meeting or in the notification of the meeting (hereinafter – “
the Postponed Meeting
.”) Notification and invitation regarding a Postponed Meeting postponed for a period of not more than 21 days shall be made not later than seventy-two hours prior to the Postponed Meeting. Notification of a Postponed Meeting shall be made as stated in section 12.6,
mutatis mutandis
.
|
13.3 |
The legal quorum for commencing a Postponed Meeting shall be any number of participants.
|
13.4 |
The chairperson of the Board of Directors shall serve as the chairperson of the general meeting. If the chairperson of the Board of Directors is absent from the meeting after 15 minutes from the time specified for the meeting, or if he refuses to serve as the chairperson of the meeting, the chairperson shall be elected by the general meeting.
|
13.5 |
A general meeting with a legal quorum is entitled to decide on the postponement of the meeting to another date and to such venue as shall be determined and, in this case, notifications and invitations to the Postponed Meeting shall be made as stated in section 13.2 above.
|
14. |
Voting at a General Meeting
|
14.1 |
A shareholder in the Company shall be entitled to vote at general meetings in person or by means of a proxy or a letter of voting.
|
14.2 |
In any vote, each shareholder shall have a number of votes equivalent to the number of shares in their possession entitling the holder to a vote.
|
14.3 |
A decision at the general meeting shall be taken by an ordinary majority unless another majority is determined in the Companies Law or in these Articles.
|
14.4 |
The declaration by the chairperson of the meeting that a decision has been adopted unanimously or by a given majority, or rejected or not adopted by a given majority, shall constitute prima facie evidence of the content thereof.
|
14.5 |
If the votes at the meeting are equally divided, the chairperson of the meeting shall not have an additional or casting opinion and the decision presented for voting shall be rejected.
|
14.6 |
Subject to any law, the shareholders in the Company are entitled to vote in any matter on the agenda of a general meeting (including type meetings) by means of a letter of voting, provided that the Board of Directors, subject to any law, has not negated in its decision to convene the general meeting the possibility of voting by means of a letter of voting on that matter.
|
14.7 |
A shareholder is entitled to state the manner of his vote in the letter of voting and to deliver this to the Company up to 48 hours prior to the time of commencement of the meeting. A letter of voting stating the manner of voting of the shareholder reaching the Company at least 48 hours prior to the time of commencement of the meeting shall be considered tantamount to presence at the meeting, including for the matter of the presence of the legal quorum as stated in section 13.1 above.
|
14.8 |
Appointment of a proxy shall be in writing, signed by the appointer (hereinafter – “
Power of Attorney
.”) A corporation shall vote by means of its representatives, who shall be appointed in a document signed properly by the corporation (hereinafter – “
Letter of Appointment
.”)
|
14.9 |
A vote in accordance with the conditions of a Power of Attorney shall be lawful even if the appointer dies before the voting, or becomes legally incompetent, is liquidated, becomes bankrupt, nullifies the Letter of Appointment, or transfers the share regarding which it was given, unless written notification is received at the Company’s office prior to the meeting that the shareholder has died, become legally incompetent, been liquidated, become bankrupt, or has nullified the Letter of Appointment or transferred the shares as stated.
|
14.10 |
The Letter of Appointment and the Power of Attorney, or a copy authorized by an attorney, shall be deposited at the Company’s registered offices at least forty eight (48) hours prior to the time determined for the meeting or for the Postponed Meeting at which the person mentioned in the document intends to vote in accordance therewith.
|
14.11 |
A shareholder in the Company shall be entitled to vote at the Company’s meetings by means of several proxies appointed thereby, provided that each proxy shall be appointed on account of different sections of the shares held by the said shareholder. There shall be no impediment to each proxy as stated voting in a different manner in the Company’s meetings.
|
14.12 |
If a shareholder is legally incompetent, he is entitled to vote by means of his trustees, the recipient of his assets, his natural guardian or other legal guardian, and these are entitled to vote in person or by proxy or a Letter of Voting.
|
14.13 |
When two or more persons are the joint owners of a share, in a vote on any matter the vote of the person whose name is registered first in the registry of shareholders as the owner of that share shall be accepted, whether in person or by proxy, and he is entitled to deliver Letters of Voting to the Company.
|
15. |
The Board of Directors
|
16. |
Appointment of the Board of Directors and Cessation of Office Thereof
|
16.1 |
The number of directors in the Company shall be determined from time to time by the annual general meeting, provided that this shall not be fewer than 5 and not more than 10 directors, including external directors. The number of external directors in the Company shall not be less than the number determined in the Companies Law.
|
16.2 |
The directors in the Company shall be elected at an annual meeting and/or an extraordinary meeting, and shall serve in their office for so long as they have not been replaced by the shareholders of the Company at an annual meeting and/or at an extraordinary meeting, or until they cease to serve in their office in accordance with the provisions of the Articles or any law, whichever is the earlier.
|
16.3 |
In addition to the content of section 16.2 above, the Board of Directors is entitled to appoint a director in place of a director whose position has become vacant and/or by way of an addition to the Board of Directors, subject to the maximum number of directors on the Board of Directors as stated in section 16.1 above. The appointment of a director by the Board of Directors shall remain valid through the next annual meeting or until the director shall cease to serve in their office in accordance with the provisions of these Articles or of any law, whichever is the earlier.
|
16.4 |
A director whose period of office has expired may be reelected, with the exception of an external director, who may be reelected for an additional period of office subject to the provisions of the law.
|
16.5 |
The office of a director shall commence on the date of their appointment by the annual meeting and/or the extraordinary meeting and/or the Board of Directors, or on a later date if this date is determined in the decision of appointment of the annual meeting and/or the extraordinary meeting and/or the Board of Directors.
|
16.6 |
The Board of Directors shall elect one of its members as the chairperson of the Board of Directors. The elected chairperson shall run the meetings of the Board of Directors and shall sign the minutes of the discussion. If no chairperson is elected, or if the chairperson of the Board of Directors is not present after 15 minutes from the time set for the meeting, the directors present shall choose one of their number to serve as the chairperson at that meeting, and the chosen member shall run the meeting and sign the minutes of the discussion.
|
16.7 |
The general meeting is entitled to transfer any director from their office prior to the end of the period of their office, inter alia whether the director was appointed thereby in accordance with section 16.2 above or was appointed by the Board of Directors in accordance with section 16.3 above, provided that the director shall be given a reasonable opportunity to state their case before the general meeting.
|
16.8 |
Any director is entitled, with the agreement of the Board of Directors, to appoint a substitute for themselves (hereinafter – “
a Substitute Director
,”) provided that a person who is not competent shall not be appointed to serve as a Substitute Director, nor a person who has been appointed as a Substitute Director for another director and/or a person who is already serving as a director in the Company.
|
16.9 |
The office of a director shall become vacant in any of the following cases:
|
16.9.1 |
He resigns from his office by means of a letter signed in his hand, submitted to the Company and detailing the reasons for his resignation;
|
16.9.2 |
He is removed from his office by the general meeting;
|
16.9.3 |
He is convicted of an offense as stated in Article 232 of the Companies Law;
|
16.9.4 |
In accordance with a court decision as stated in Article 233 of the Companies Law;
|
16.9.5 |
He is declared legally incompetent;
|
16.9.6 |
He is declared bankrupt and, if the director is a corporation – it opted for voluntary liquidation or a liquidation order was issued against it.
|
16.10 |
In the event that the position of a director becomes vacant, the remaining directors shall be entitled to continue to act, provided the number of directors remaining shall not be less than the minimum number of directors as stated above in section 16.1 above. If the number of directors falls below the above-mentioned minimum number, the remaining directors shall be entitled to act solely in order to fill the place of the director that has become vacant as stated in section 16.3 above, or in order to convene a general meeting of the Company, and pending the convening of the general meeting of the Company as stated they may act to manage the Company’s affairs solely in matters that cannot be delayed.
|
16.11 |
The conditions of office of the members of the Board of Directors shall be authorized in accordance with the provisions of the Companies Law.
|
17. |
Meetings of the Board of Directors
|
17.1 |
The Board of Directors shall convene for a meeting in accordance with the needs of the Company, and at least once every three months.
|
17.2 |
The chairperson of the Board of Directors is entitled to convene the Board at any time. In addition, the Board of Directors shall hold a meeting on such subject as shall be specified in the following cases:
|
17.2.1 |
In accordance with the request of two directors; however, if at the time the Board of Directors comprises five directors or less – in accordance with the request of one director;
|
17.2.2 |
In accordance with the request of one director if, in his request to convene the Board, he states that he has learned of a matter in the Company ostensibly entailing a violation of the law or infringement of proper business practice;
|
17.2.3 |
If a general director has been appointed in the Company or if a notification or report by the general director require an action on the part of the Board of Directors;
|
17.2.4 |
If the auditing accountant has informed the chairperson of the Board of Directors – or, in the event that no chairperson was appointed for the Board of Directors, has informed the Board of Directors – of substantial defects in the accounting control of the Company.
|
17.3 |
Notification of the meeting of the Board of Directors shall be delivered to all members of the Board at least three days prior to the date of convening of the Board, or with shorter prior notice insofar as the chairperson of the Board decided that, in the circumstances of the matter, it is vital and reasonable to convene the Board of Directors with notice shorter than three days. Notification shall be delivered to the address of the director as forwarded to the Company in advance, and shall stipulate the time of the meeting and the venue at which it shall convene, as well as reasonable detail of all subjects on the agenda.
|
17.4 |
The agenda of the meetings of the Board of Directors shall be determined by the chairperson of the Board and shall include: Subjects determined by the chairperson of the Board; subjects deriving from the report of the general director and/or the auditing accountant; any subject a director of the general director have requested of the chairperson of the Board to include on the agenda, at least two days prior to the convening of the meeting of the Board.
|
17.5 |
The details of the subjects on the agenda as stated in section 17.4 above do not prevent discussion of a subject or subjects not mentioned in the notification of the meeting of the Board of Directors (hereinafter: “
a New Subject
.”)
|
17.6 |
The legal quorum for the commencement of a meeting of the Board of Directors shall be a majority of the members of the Board of Directors. If, at the end of one half-hour from the time set for the commencement of the meeting, no quorum is present, the meeting shall be postponed to another date as decided by the chairperson of the Board, or, in his absence, by the directors present at the convened meeting, provided that prior notification of three days shall be given to all directors regarding the date of the Postponed Meeting. The legal quorum for the opening of a Postponed Meeting shall be any number of participants.
|
17.7 |
The Board of Directors is entitled to hold meetings by use of any means of communication, providing that all the participating directors can hear each other simultaneously.
|
17.8 |
The Board of Directors is entitled to take decisions without actually convening, provided that all the directors entitled to participate in the discussion and to vote on the subject brought for decision agree thereto. If decisions are made as stated in this section, the chairperson of the Board of Directors shall record minutes of the decisions stating the manner of voting of each director on the subjects brought for decision, as well as the fact that all the directors agreed to take the decision without convening.
|
18. |
Voting on the Board of Directors
|
18.1 |
Each director shall have one vote when voting on the Board of Directors.
|
18.2 |
Decisions of the Board of Directors shall be taken by a majority vote. The chairperson of the Board of Directors shall not have any additional or casting opinion, and in the event of a tie vote, the decision brought for voting shall be rejected.
|
19. |
Committees of the Board of Directors
|
19.1 |
The Board of Directors is entitled to establish committees and to appoint members thereto (hereinafter – “
the Committees of the Board of Directors
.”) If Committees of the Board of Directors are established, the Board of Directors shall determine, in the conditions of empowerment thereof, whether specific authorities of the Board of Directors shall be delegated to the Committees of the Board of Directors, in such manner that the decision of the Committee of the Board of Directors shall be considered tantamount to a decision of the Board of Directors, or whether the decision of the Committee of the Board of Directors shall merely constitute a recommendation, subject to the authorization of the Board of Directors; provided that authorities to make decisions in the matters stated in Article 112 of the Companies Law shall not be delegated to a committee.
|
19.2 |
A person who is not a director shall not serve in a Committee of the Board of Directors to which the Board of Directors has delegated authorities. Persons who are not members of the Board of Directors may serve in a Committee of the Board of Director whose function is merely to advise or submit recommendations to the Board of Directors.
|
19.3 |
The provisions included in these Articles relating to the meetings of the Board of Directors and voting therein shall apply,
mutatis mutandis
and subject to the decisions of the Board of Directors regarding the procedures for the meetings of the committee (if any), to any Committee of the Board of Directors comprising two or more members.
|
20. |
Audit Committee
|
20.1 |
The Board of Directors of the Company shall appoint an audit committee from among its members. The number of members of the audit committee shall be not less than three, and any external director may be a member thereof. The chairperson of the Board of Directors or any director employed by the Company, or providing it with services on a regular basis, or a controlling shareholder in the Company, or a relative thereof shall not be appointed to the committee.
|
20.2 |
The functions of the audit committee shall be –
|
20.2.1 |
To identify defects in the business management of the Company, inter alia through consultation with the internal auditor of the Company or the auditing accountant, and to propose methods to the Board of Directors for correcting these;
|
20.2.2 |
To decide whether to authorize actions and transactions requiring the authorization of the audit committee in accordance with the Companies Law.
|
21. |
General Director
|
22. |
Exemption, Insurance, and Indemnification
|
22.1 |
enter into a contract for the insurance of the liability, in whole or in part, of any of its “Office Holders” (as defined in the Companies Law) with respect to an obligation imposed on such Office Holder due to an act performed by the Office Holder in the Office Holder’s capacity as an Office Holder of the Company arising from any of the following:
|
22.1.1 |
a breach of duty of care to the Company or to any other person;
|
22.1.2 |
a breach of the duty of loyalty to the Company provided that the Office Holder acted in good faith and had reasonable grounds to assume that the act would not harm the interests of the Company;
|
22.1.3 |
a financial liability imposed on such Office Holder in favor of any other person:
|
22.1.4 |
reasonable litigation expenses, including attorneys fees, incurred by the Office Holder as a result of an ongoing administrative enforcement proceeding instituted against him in accordance with the Israeli Securities Law. Without derogating from the generality of the foregoing, such expenses will include, and the Company may procure insurance for, a payment imposed on the Office Holder in favor of an injured party as set forth in Section 52CIV(a)(1)(a) of the Israeli Securities Law and expenses that the Office Holder incurred in connection with a proceeding under Chapters VIII”3, VIII”4 or IX”1 of the Israeli Securities Law, including reasonable legal expenses, which term includes attorney fees; and
|
22.1.5 |
any other incident for which it is or shall be permitted to insure the liability of an officer.
|
22.2 |
undertake, in advance to indemnify, or may indemnify retroactively, an Office Holder of the Company with respect to any of the following liabilities or expenses that arise from an act performed by the Office Holder by virtue of being an Office Holder of the Company:
|
22.2.1 |
a financial liability imposed on an Office Holder in favor of another person by any judgment, including a judgment given as a result of a settlement or an arbitrator’s award which has been confirmed by a court;
|
22.2.2 |
reasonable litigation expenses including attorney’s fees, incurred by him as a result of an investigation or proceeding instituted against him by an authority empowered to conduct an investigation or proceedings, which are concluded without the filing of an indictment against the Office Holder and without the levying of a monetary obligation in lieu of criminal proceedings upon the Office Holder, or which are concluded without the filing of an indictment against the Office Holder but with levying a monetary obligation in substitute of such criminal proceedings upon the Office Holder for a crime that does not require proof of criminal intent; or in connection with an administrative enforcement proceeding or a financial sanction. Without derogating from the generality of the foregoing, such expenses will include, and the Company may undertake to indemnify an Office Holder of the Company as aforesaid, for a payment imposed on the Office Holder in favor of an injured party as set forth in Section 52LIV(a)(1)(a) of the Israeli Securities Law and expenses that the Office Holder incurred in connection with a proceeding under Chapters VIII”3, VIII”4 or IX’1 of the Israeli Securities Law, including reasonable legal expenses, which term includes attorney fees; and
|
22.2.3 |
reasonable litigation expenses, including attorney’s fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed against the Office Holder by the Company or in its name or by any other person or in a criminal charge on which the Office Holder was acquitted or in a criminal charge on which the Office Holder was convicted for an offense which did not require proof of criminal intent; and
|
22.2.4 |
any other obligation or expense for which it is or shall be permitted to indemnify an officer, provided however, that in the event the Company wishes to indemnify an Office Holder in advance for financial liabilities under Article 22 it may only do so if the undertaking to indemnify the Office Holder for such liabilities was restricted to those events that the Board may deem foreseeable in light of the Company’s actual activities, at the time of giving of such undertaking, and to a specific sum or a reasonable criterion under such circumstances as determined by the Board.
|
23. |
Subject to the provisions of the Law and the Israeli Securities Law, the Company hereby releases, in advance, its Office Holders from liability to the Company for damage that arises from the breach of the Office Holder’s duty of care to the Company.
|
24. |
The provisions of Articles 22 and 23 are not intended, and shall not be interpreted, to restrict the Company in any manner in respect of the procurement of insurance or in respect of indemnification (i) in connection with any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder, or (ii) in connection with any Office Holder to the extent that such insurance and/ or indemnification is not specifically prohibited under the Companies Law; provided that the procurement of any such insurance or the provision of any such indemnification shall be approved by the Board. Any modification of Articles 22 through 24, and any amendment to the Companies Law, the Israeli Securities Law or any other applicable law, shall be prospective in effect and shall not affect the Company’s obligation or ability to indemnify an Office Holder for any act or omission occurring prior to such modification or amendment, unless otherwise provided by the Companies Law, the Israeli Securities Law or such applicable law.
|
25. |
Internal Auditor
|
25.1 |
The Board of Directors of the Company shall appoint an internal auditor in accordance with the proposal of the audit committee. A person who is an interested party in the Company, an office holder therein, or the relative or either of the above, as well as the auditing accountant or any person on his behalf, shall not serve as an internal auditor in the Company.
|
25.2 |
The Board of Directors shall determine which office holder shall be organizationally accountable for the internal auditor and, in the absence of such determination; this shall be the chairperson of the Board of Directors.
|
25.3 |
The internal audit plan prepared by the auditor shall be submitted to the audit committee for authorization; however, the Board of Directors is permitted to determine that the plan shall be submitted to the Board of Directors for authorization.
|
26. |
Auditing Accountant
|
26.1 |
The general meeting shall appoint an auditing accountant for the Company. The auditing accountant shall service in his office through the end of the following annual meeting, or for a longer period as determined by the annual meeting, provided that the period of office shall not be extended beyond the end of the third annual meeting following that at which he was appointed.
|
26.2 |
The fee of the auditing accountant for the auditing operations shall be determined by the Board of Directors. The Board of Directors shall report to the annual meeting on the fee of the auditing accountant.
|
27. |
Signing in the Company’s Name
|
27.1 |
The rights to sign in the Company’s name shall be determined from time to time by the Board of Directors of the Company.
|
27.2 |
The Company’s authorized signatory shall do so together with the Company’s stamp, or alongside its printed name.
|
28. |
Dividend and Benefit Shares
|
28.1
|
The decision by the Company to allocate a dividend and/or to allocate benefit shares shall be taken by the Company’s Board of Directors.
|
28.2 |
Unless determined otherwise by the Board of Directors, it shall be permitted to pay any dividend by way of check or payment order to be sent by mail in accordance with the registered address of the shareholder or the personal eligible thereto or, in the case of joint registered owners of the same share, to that shareholder whose name is mentioned first in the registry of shareholders with regard to the joint ownership. Any such check shall be made out to order of the person to whom it is sent. A receipt from a person whose name, as of the date of declaration of the dividend, is registered in the registry of shareholders as the owner of any share or, in the case of joint owners, of one of the joint owners, shall serve as authorization regarding all payments made in connection with that share and regarding which the receipt was received.
|
28.3 |
For the purpose of executing any decision in accordance with the provisions of this section, the Board of Directors is entitled to resolve as it sees fit any difficulty that emerges regarding distribution of the dividend and/or the benefit shares, including determining the value for the purpose of the said division of certain assets, and to determine that payments in cash shall be made to members on the basis of the value so determined; to determine provisions regarding fractions of shares; or to determine that sums of less than NIS 50 shall not be paid to a shareholder.
|
29. |
Redeemable Securities
|
30. |
Donations
|
31. |
Accounts
|
31.1 |
The Company shall maintain accounts and shall prepare financial statements in accordance with the Securities Law and in accordance with any law.
|
31.2 |
The account ledgers shall be held at the Company’s registered offices or in any other place as the directors shall see fit, and shall always be open for inspection by the directors.
|
32. |
Notifications
|
32.1 |
Subject to any law, a notification or any other document that shall be delivered by the Company, and which it is entitled or required to issue in accordance with the provisions of the Articles and/or the Companies Law, the Securities Law, or any law, shall be delivered by the Company to any person in one of the following manners as decided by the Company in each individual case: (A) By dispatch by registered mail in a letter addressed in accordance with the registered address of that shareholder in the registry of shareholders, or in accordance with such address as stated by the shareholder in a letter to the Company as the letter for the delivery of notifications or other documents; or (B) By dispatch by facsimile in accordance with the number stated by the shareholder as the number for the delivery of facsimile notifications; or (C) By way of publication in two daily newspapers appearing in Israel; or (D) By way of publication in the distribution site of the Securities Authority and the Tel Aviv Stock Exchange Ltd.
|
32.2 |
Any notification to be made to shareholders shall be made, regarding jointly owned shares, to that person whose name is mentioned first in the registry of shareholders as the holder of that share, and any notification made in this manner shall be sufficient notification for the holders of that share.
|
32.3 |
Any notification or other document sent in accordance with the provisions of section 30.1 above shall be considered to have reached its destination: (A) Within 3 business days – if sent by registered mail in Israel; or (B) On the first business day after its dispatch, if delivered by hand or sent by facsimile; or (C) On the date of publication, if published in a newspaper or on the distribution site of the Securities Authority and the Tel Aviv Stock Exchange Ltd.
|
32.4 |
Any record made in an ordinary manner in the company’s registry shall be considered prima facie evidence of dispatch as recorded in that registry.
|
32.5 |
When it is necessary to provide prior notification of a certain number of days, or when notification is valid for a certain period, the date of delivery shall be included in reckoning the number of days or the period.
|
Yigal Arnon (1929-2014)
Dror Vigdor
Amalia Meshi
Amnon Lorch
Hagai Shmueli
Barry Levenfeld
David H. Schapiro
Hagit Bavly
Orna Sasson
Barak Tal
Shiri Shaham
Doron Tamir
Daniel Abarbanel
David Osborne
Gil Oren
Ronit Amir
Orly Tsioni
Mordehai Baicz
Barak Platt
Benjamin Horef
Yoran Gill
Asaf Eylon
Daniel Marcovici
Adrian Daniels
Yuval Shalheveth
Jacob Ben Chitrit
Peter Sugarman
Ben Sandler
Boaz Fiel
Joeri Kreisberg
Simon Weintraub
|
Ruth Loven
Yarom Romem
Adam Spruch
Yuval Bargil
Eliran Furman
Eran Lempert
Ofir Levy
Daniel Green
Hanital Belinson
Yoheved Novogroder
Oren Roth Dror Varsano
Odelia Sidi
Shira Lahat
Ido Chitman
Noa Afik
Aner Hefetz
David Akrish
Nir Rosner
Assaf Mesica
Liron Hacohen
Guy Fuhrer
Ezra Gross
David Roness
Eli Greenbaum
Lee Maor
Nimrod Vromen
Guy Sagiv
Micha Tollman
Shani Rapoport
Lior Gelbard
|
Michal Sagmon
Hila Roth
Keren Tal
Neta Goshen
Roy Masuri
Eyal Yacoby
Daphna Livneh
Tamar Gilboa
Yael Hoefler
Sagi Schiff
Lilach Grimberg
Adi Samuel
Netanella Treistman
Daniel Damboritz
Shlomi Schneider
Alona Toledano
Elad Offek
Yuval Shamir
Dana Heller
Adi Tal
Yulia Lazbin
Joshua Lieberman
Liat Pillersdorf
Orly Rottenberg
Avi Anouchi
Shay Fahima
Michael Keren
Sivan Gilron Dotan
Naftali Nir
Tomer Bar-Nathan Evan Schendler |
Lihi Katzenelson
Eyal Aichel
Shahar Uziely
Edan Regev
Yehudit Biton
Ohad Shalem
Gitit Ramot-Adler
Omri Schnaider
Rinat Michael
Adi Attar Ivor Krumholtz
Daniella Milner
Harel Sinai
Amos Oseasohn
Guy Kortany
Goor Koren
Adi Daniel Dafna Shaham Miriam Friedmann
Itamar Lippner
Ricki Newman
Roni Osborne
Ortal Zanzuri
Reut Sasson
Josh Hersch Roey Sasson
Shir Eshkol
Nir Rodnizky
Noa Slavin
Guy Fatal Shani Lorch |
Ira Burshtein
Elichai Bitter
Amir Weiser
Itamar Cohen
Shai Margalit
Yossi Paloch
Ofir Schwartz Meital Singer
Yonatan Whitefield
Moshe Lankry
Shira Teger
Rachel Lerman
Ravid Saar
Debbie Shalit
Sophie Blackston
Eti Elbaz
Hagar Mizrachi
Elad Morgenstern Ron Ashkenazi
Dafna Raz
Sara Haber
Erez Leibovich
Ilan Akouka
Shlomit Bukaya
Yehonatan Cohen
David Shmulevitz
Tair Cherbakovsky
Ophir Dagan
Yael Meretyk Hanan
Dov Ehrman
Nataly Damary |
Noam Pratzer
Nava Rozolyo
Shiran Glitman
Dor Daniel
Michael Rosenblit
Heni Rothstein-Cohen
Gal Frenkel
Dani Weissberg
Lareine Khoury
Nohar Hadar
Shirley Youseri
Nitzan Kahana
Yahel Kaplan
Liad Kalderon
Daniel Szriber
Shachar Hindi
Natalie Korenfeld
Moshe Pasker
Mazi Ohayon
Daniel Rosenblatt
Nitzan Fisher-Conforti
Victoria Savu
Derora Tropp
_______________________
Paul H. Baris (1934-2010)
Rami Kook
Nira Kuritzky
Eran Ilan
|
Very truly yours,
|
||
|
||
/s/ Yigal Arnon & Co.
|
||
Yigal Arnon & Co.
|
|
1 Azrieli Center, Tel Aviv, 6702101 | Phone: +972-3-6087777 | Fax: +972-3-6087724
31 Hillel Street, Jerusalem, 9458131 | Phone: +972-2-6239239 | Fax: +972-2-6239233
www.arnon.co.il | info@arnon.co.il
|
|
250 WEST 55TH STREET
NEW YORK, NY 10019-9601
TELEPHONE: 212.468.8000
FACSIMILE: 212.468.7900
WWW.MOFO.COM
|
MORRISON & FOERSTER LLP
BEIJING, BERLIN, BRUSSELS,
DENVER, HONG KONG, LONDON, LOS ANGELES, NEW YORK, NORTHERN VIRGINIA, PALO ALTO, SAN DIEGO, SAN FRANCISCO, SHANGHAI, SINGAPORE, TOKYO, WASHINGTON, D.C |
Re: |
BioLineRx Ltd.
─
Shelf Registration Statement on Form F-3
|
Exhibit 12.1
|
||||||
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
|
Nine Months
ended
September 30,
|
||||||||||||||||||||||||
2012
|
2013
|
2014
|
2015
|
2016
|
2017
|
|||||||||||||||||||
EARNINGS
|
||||||||||||||||||||||||
Pre-tax earnings from continuing operations
|
(19,163
|
)
|
(15,437
|
)
|
(9,955
|
)
|
(14,401
|
)
|
(15,841
|
)
|
(16,995
|
)
|
||||||||||||
Add back:
|
||||||||||||||||||||||||
Fixed charges
|
81
|
69
|
74
|
112
|
113
|
90
|
||||||||||||||||||
(19,082
|
)
|
(15,368
|
)
|
(9,881
|
)
|
(14,289
|
)
|
(15,728
|
)
|
(16,905
|
)
|
|||||||||||||
FIXED CHARGES
|
||||||||||||||||||||||||
Interest expensed and capitalized
|
5
|
-
|
-
|
2
|
4
|
3
|
||||||||||||||||||
Estimate of interest within rental expense
|
76
|
69
|
74
|
111
|
110
|
87
|
||||||||||||||||||
81
|
69
|
74
|
112
|
113
|
90
|
|||||||||||||||||||
RATIO OF EARNINGS TO FIXED
CHARGES FOR F-3
|
(20,236
|
)
|
(16,301
|
)
|
(10,512
|
)
|
(14,401
|
)
|
(15,841
|
)
|
(16,995
|
)
|
Tel-Aviv, Israel
|
/
s
/
Kesselman & Kesselman
|
December 28, 2017
|
Certified Public Accountants (Isr.)
|
A member firm of PricewaterhouseCoopers International Limited
|
New York
(Jurisdiction of incorporation if not a U.S. national bank) |
13-5160382
(I.R.S. employer identification no.) |
225 Liberty Street, New York, N.Y.
(Address of principal executive offices) |
10286
(Zip code) |
State of Israel
(State or other jurisdiction of incorporation or organization) |
Not Applicable
(I.R.S. employer identification no.) |
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of principal executive offices) |
(Zip code) |
1. |
General information. Furnish the following information as to the Trustee:
|
(a) |
Name and address of each examining or supervising authority to which it is subject.
|
Name
|
Address
|
Superintendent of the Department of Financial Services of the State of New York
|
One State Street, New York, N.Y. 10004-1417, and Albany, N.Y. 12223
|
Federal Reserve Bank of New York
|
33 Liberty Street, New York, N.Y. 10045
|
Federal Deposit Insurance Corporation
|
550 17
th
Street, NW Washington, D.C. 20429
|
The Clearing House Association L.L.C.
|
100 Broad Street New York, N.Y. 10004
|
(b) |
Whether it is authorized to exercise corporate trust powers.
|
2. |
Affiliations with Obligor.
|
16. |
List of Exhibits.
|
1. |
A copy of the Organization Certificate of The Bank of New York Mellon (formerly known as The Bank of New York, itself formerly Irving Trust Company) as now in effect, which contains the authority to commence business and a grant of powers to exercise corporate trust powers. (Exhibit 1 to Amendment No. 1 to Form T-1 filed with Registration Statement No. 33-6215, Exhibits 1a and 1b to Form T-1 filed with Registration Statement No. 33-21672, Exhibit 1 to Form T-1 filed with Registration Statement No. 33-29637, Exhibit 1 to Form T-1 filed with Registration Statement No. 333-121195 and Exhibit 1 to Form T-1 filed with Registration Statement No. 333-152735).
|
4. |
A copy of the existing By-laws of the Trustee (Exhibit 4 to Form T-1 filed with Registration Statement No. 333-207042).
|
6. |
The consent of the Trustee required by Section 321(b) of the Act (Exhibit 6 to Form T-1 filed with Registration Statement No. 333-188382).
|
7. |
A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements of its supervising or examining authority.
|
|
THE BANK OF NEW YORK MELLON
By:
/s/ Francine Kincaid
Name: Francine Kincaid Title: Vice President |
ASSETS
|
Dollar amounts in thousands
|
|||
Cash and balances due from depository institutions:
|
||||
Noninterest-bearing balances and currency and coin
|
4,915,000
|
|||
Interest-bearing balances
|
89,278,000
|
|||
Securities:
|
||||
Held-to-maturity securities
|
39,433,000
|
|||
Available-for-sale securities
|
76,289,000
|
|||
Federal funds sold and securities purchased under agreements to resell:
|
||||
Federal funds sold in domestic offices
|
0
|
|||
Securities purchased under agreements to resell
|
14,181,000
|
|||
Loans and lease financing receivables:
|
||||
Loans and leases held for sale
|
0
|
|||
Loans and leases held for investment
|
29,492,000
|
|||
LESS: Allowance for loan and lease losses
|
136,000
|
|||
Loans and leases held for investment, net of allowance
|
29,356,000
|
|||
Trading assets
|
3,201,000
|
|||
Premises and fixed assets (including capitalized leases)
|
1,386,000
|
|||
Other real estate owned
|
4,000
|
|||
Investments in unconsolidated subsidiaries and associated companies
|
584,000
|
|||
Direct and indirect investments in real estate ventures
|
0
|
|||
Intangible assets:
|
||||
Goodwill
|
6,378,000
|
|||
Other intangible assets
|
861,000
|
|||
Other assets
|
15,476,000
|
|||
Total assets
|
281,342,000
|
|||
LIABILITIES
|
||||
Deposits:
|
||||
In domestic offices
|
120,206,000
|
|||
Noninterest-bearing
|
74,342,000
|
|||
Interest-bearing
|
45,864,000
|
|||
In foreign offices, Edge and Agreement subsidiaries, and IBFs
|
116,952,000
|
|||
Noninterest-bearing
|
6,351,000
|
|||
Interest-bearing
|
110,601,000
|
|||
Federal funds purchased and securities sold under agreements to repurchase:
|
||||
Federal funds purchased in domestic offices.
|
260,000
|
|||
Securities sold under agreements to repurchase
|
2,833,000
|
|||
Trading liabilities
|
2,409,000
|
|||
Other borrowed money:
(includes mortgage indebtedness and obligations under capitalized leases) |
4,522,000
|
|||
Not applicable
|
||||
Not applicable
|
||||
Subordinated notes and debentures
|
515,000
|
|||
Other liabilities
|
6,939,000
|
|||
Total liabilities
|
254,636,000
|
|||
EQUITY CAPITAL
|
||||
Perpetual preferred stock and related surplus
|
0
|
|||
Common stock
|
1,135,000
|
|||
Surplus (exclude all surplus related to preferred stock)
|
10,744,000
|
|||
Retained earnings
|
15,995,000
|
|||
Accumulated other comprehensive income
|
(1,518,000
|
) | ||
Other equity capital components
|
0
|
|||
Total bank equity capital
|
26,356,000
|
|||
Noncontrolling (minority) interests in consolidated subsidiaries
|
350,000
|
|||
Total equity capital
|
26,706,000
|
|||
Total liabilities and equity capital
|
281,342,000
|
Gerald L. Hassell
Samuel C. Scott Joseph J. Echevarria |
Directors
|